Michael E. Thase, MD

Original Research

Desvenlafaxine 50 and 100 mg/d Versus Placebo for the Treatment of Major Depressive Disorder: A Phase 4, Randomized Controlled Trial

October 28, 2014

Anita H. Clayton, Karen A. Tourian, Kristen Focht, et al

Commentary

Depression: Addressing Partial Response After First-Line Antidepressant Treatment

September 25, 2014

Michael E. Thase, Maurizio Fava, Andrew A. Nierenberg

Educational Activity

Translating Clinical Science Into Effective Therapies

June 15, 2014

Michael E. Thase

Article

A Review of Vilazodone, Serotonin, and Major Depressive Disorder

January 9, 2014

The efficacy and safety of vilazodone was established in 2 positive Phase III clinical trials in adult patients with MDD. This article provides a brief overview of the serotonin...

Kerri A. Pierz, Michael E. Thase

Original Research

Influence of Sex and Menopausal Status on Response, Remission, and Recurrence in Patients With Recurrent Major Depressive Disorder Treated With Venlafaxine Extended Release or Fluoxetine: Analysis of Data From the PREVENT Study

November 26, 2013

Susan G. Kornstein, Ronald D. Pedersen, Peter J. Holland, et al

Original Research

The Prevalence and Severity of Depressive Symptoms Along the Spectrum of Unipolar Depressive Disorders: A Post Hoc Analysis

November 15, 2013

Jeffrey J. Rakofsky, Pamela J. Schettler, Becky L. Kinkead, et al

Educational Activity

Residual Symptoms and the Risk of Relapse in Major Depression

November 15, 2013

Michael E. Thase

DELETE Managing the Full Range of Symptoms to Achieve Lasting Remission

The Multifactorial Presentation of Depression in Acute Care

October 29, 2013

Michael E. Thase

Article

The Multifactorial Presentation of Depression in Acute Care

October 15, 2013

Michael E. Thase

ASCP Corner

Monoamine Oxidase Inhibitors Revisited: What You Should Know

February 15, 2013

Joseph F. Goldberg, Michael E. Thase

Supplement Article

Discussion: A Fresh Look at Monoamine Oxidase Inhibitors for Depression

July 27, 2012

Lawrence J. Cohen, David A. Sclar, Larry Culpepper, et al

Supplement Article

The Role of Monoamine Oxidase Inhibitors in Depression Treatment Guidelines

July 27, 2012

Michael E. Thase

Desvenlafaxine 50 and 100 mg/d Versus Placebo for the Treatment of Major Depressive Disorder: A Phase 4, Randomized Controlled Trial

Depression: Addressing Partial Response After First-Line Antidepressant Treatment

Translating Clinical Science Into Effective Therapies

A Review of Vilazodone, Serotonin, and Major Depressive Disorder

Influence of Sex and Menopausal Status on Response, Remission, and Recurrence in Patients With Recurrent Major Depressive Disorder Treated With Venlafaxine Extended Release or Fluoxetine: Analysis of Data From the PREVENT Study

The Prevalence and Severity of Depressive Symptoms Along the Spectrum of Unipolar Depressive Disorders: A Post Hoc Analysis

Residual Symptoms and the Risk of Relapse in Major Depression

The Multifactorial Presentation of Depression in Acute Care

The Multifactorial Presentation of Depression in Acute Care

Monoamine Oxidase Inhibitors Revisited: What You Should Know

Discussion: A Fresh Look at Monoamine Oxidase Inhibitors for Depression

The Role of Monoamine Oxidase Inhibitors in Depression Treatment Guidelines

ELSEWHERE:

FOLLOW US:

Michael E. Thase, MD

Desvenlafaxine 50 and 100 mg/d Versus Placebo for the Treatment of Major Depressive Disorder: A Phase 4, Randomized Controlled Trial

Depression: Addressing Partial Response After First-Line Antidepressant Treatment

Translating Clinical Science Into Effective Therapies

A Review of Vilazodone, Serotonin, and Major Depressive Disorder

Influence of Sex and Menopausal Status on Response, Remission, and Recurrence in Patients With Recurrent Major Depressive Disorder Treated With Venlafaxine Extended Release or Fluoxetine: Analysis of Data From the PREVENT Study

The Prevalence and Severity of Depressive Symptoms Along the Spectrum of Unipolar Depressive Disorders: A Post Hoc Analysis

Residual Symptoms and the Risk of Relapse in Major Depression

The Multifactorial Presentation of Depression in Acute Care

The Multifactorial Presentation of Depression in Acute Care

Monoamine Oxidase Inhibitors Revisited: What You Should Know

Discussion: A Fresh Look at Monoamine Oxidase Inhibitors for Depression

The Role of Monoamine Oxidase Inhibitors in Depression Treatment Guidelines

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles